Nasdaq Announces Changes to Nasdaq-100 Index®; Pfizer to Acquire Seagen, Inc.\n\nNasdaq, Inc. has announced an update to the annual reconstitution of the Nasdaq-100 Index®. The pending acquisition of Seagen, Inc. by Pfizer Inc. is expected to close on December 14, 2023. As a result, Take-Two Interactive Software, Inc. Will be added to the Nasdaq-100 Index® and Seagen, Inc. will be removed. The other constituent changes from the initial announcement by Nasdaq on Friday, December 8, 2023, will remain the same.\n\nTake-Two Interactive Software, Inc. (TTWO) is a leading global technology company serving corporate clients, investment managers, banks, brokers, and exchange operators. The company’s diverse offering of data, analytics, software, exchange capabilities, and client-centric services enables clients to optimize and execute their business vision with confidence. The company’s strong fundamentals and strategic initiatives have led to impressive results.\n\nNasdaq Global Indexes has been creating innovative, market-leading, transparent indexes since 1971. Today, their index offering spans geographies and asset classes, providing new opportunities for financial product sponsors and asset managers. Nasdaq also provides exchange listing, custom index, and design solutions to financial organizations worldwide.\n\nStatements regarding Nasdaq’s proprietary indexes are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. \n\nThe latest trading session saw Pfizer (PFE) ending at $28.58, denoting a -0.21% adjustment from its last days close. The stock trailed the S&P 500, which registered a daily gain of 0.46%. Elsewhere, the Dow gained 0.48%, while the tech-heavy Nasdaq added 0.7%. The drugmaker’s stock has dropped by 1.17% in the past month, falling short of the Medical sector’s gain of 4.8% and the S&P 500’s gain of 4.85%. The investment community will be paying close attention to the earnings performance of Pfizer in its upcoming release. The company’s earnings per share (EPS) are projected to be -$0.16, reflecting a 114.04% decrease from the same quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $14.58 billion, down 39.98% from the year-ago period. Regarding profitability, Pfizer has posted a gross margin of 79.86%.\n\nIn a Nasdaq’s update to the annual reconstitution of the Nasdaq-100 Index® highlights the company’s strong fundamentals and strategic initiatives. The pending acquisition of Seagen, Inc. by Pfizer Inc. is expected to close on December 14, 2023, resulting in Take-Two Interactive Software, Inc. Being added to the index.
“Nasdaq Announces Changes to Nasdaq-100 Index®; Pfizer to Acquire Seagen, Inc.\n\nNasdaq, Inc. has announced an update to the annual reconstitution of the Nasdaq-100 Index®. The pending acquisition of Seagen, Inc. by Pfizer Inc. is expected to close on December 14, 2023. As a result, Take-Two Interactive Software, Inc. Will be added to the Nasdaq-100 Index® and Seagen, Inc. will be removed. The other constituent changes from the initial announcement by Nasdaq on Friday, December 8, 2023, will remain the same.\n\nTake-Two Interactive Software, Inc. (TTWO) is a leading global technology company serving corporate clients, investment managers, banks, brokers, and exchange operators. The company’s diverse offering of data, analytics, software, exchange capabilities, and client-centric services enables clients to optimize and execute their business vision with confidence. The company’s strong fundamentals and strategic initiatives have led to impressive results.\n\nNasdaq Global Indexes has been creating innovative, market-leading, transparent indexes since 1971. Today, their index offering spans geographies and asset classes, providing new opportunities for financial product sponsors and asset managers. Nasdaq also provides exchange listing, custom index, and design solutions to financial organizations worldwide.\n\nStatements regarding Nasdaq’s proprietary indexes are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. \n\nThe latest trading session saw Pfizer (PFE) ending at $28.58, denoting a -0.21% adjustment from its last days close. The stock trailed the S&P 500, which registered a daily gain of 0.46%. Elsewhere, the Dow gained 0.48%, while the tech-heavy Nasdaq added 0.7%. The drugmaker’s stock has dropped by 1.17% in the past month, falling short of the Medical sector’s gain of 4.8% and the S&P 500’s gain of 4.85%. The investment community will be paying close attention to the earnings performance of Pfizer in its upcoming release. The company’s earnings per share (EPS) are projected to be -$0.16, reflecting a 114.04% decrease from the same quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $14.58 billion, down 39.98% from the year-ago period. Regarding profitability, Pfizer has posted a gross margin of 79.86%.\n\nIn a Nasdaq’s update to the annual reconstitution of the Nasdaq-100 Index® highlights the company’s strong fundamentals and strategic initiatives. The pending acquisition of Seagen, Inc. by Pfizer Inc. is expected to close on December 14, 2023, resulting in Take-Two Interactive Software, Inc. Being added to the index.”$PFE2023-12-15T06:32:38.429Z